30
Participants
Start Date
April 2, 2024
Primary Completion Date
November 30, 2027
Study Completion Date
November 30, 2027
BioTTT001 intraperitoneal infusion
Monotherapy lead-in phase: BioTTT01 1×10\^10 VP, i.p., D1 and D3; Combination therapy phase: BioTTT01 1×10\^10 VP, i.p., D1 and D3, 3 weeks per cycle
SOX regimen
Combination therapy phase: Oxaliplatin 130 mg，i.v., D1 and D3, 3 weeks per cycle; Tegafur 40\~60mg b.i.d. p.o. D1\~D14; 3 weeks per cycle
toripalimab
Combination therapy phase: toripalimab 160mg i.v. D1, 3 weeks per cycle.
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
INDUSTRY
China Medical University, China
OTHER